Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

The transcription factor ERG regulates a low shear stress-induced anti-thrombotic pathway in the microvasculature.

Peghaire C, Dufton NP, Lang M, Salles-Crawley II, Ahnström J, Kalna V, Raimondi C, Pericleous C, Inuabasi L, Kiseleva R, Muzykantov VR, Mason JC, Birdsey GM, Randi AM.

Nat Commun. 2019 Nov 1;10(1):5014. doi: 10.1038/s41467-019-12897-w.

2.

Cross-linker-Modulated Nanogel Flexibility Correlates with Tunable Targeting to a Sterically Impeded Endothelial Marker.

Myerson JW, McPherson O, DeFrates KG, Towslee JH, Marcos-Contreras OA, Shuvaev VV, Braender B, Composto RJ, Muzykantov VR, Eckmann DM.

ACS Nano. 2019 Oct 22;13(10):11409-11421. doi: 10.1021/acsnano.9b04789. Epub 2019 Oct 10.

PMID:
31600053
3.

CRISPR/Cas9-Mediated Genetic Engineering of Hybridomas for Creation of Antibodies that Allow for Site-Specific Conjugation.

Khoshnejad M, Brenner JS, Parhiz H, Muzykantov VR.

Methods Mol Biol. 2019;2033:81-93. doi: 10.1007/978-1-4939-9654-4_7.

PMID:
31332749
4.

Endothelial Targeted Strategies to Combat Oxidative Stress: Improving Outcomes in Traumatic Brain Injury.

Lutton EM, Farney SK, Andrews AM, Shuvaev VV, Chuang GY, Muzykantov VR, Ramirez SH.

Front Neurol. 2019 Jun 6;10:582. doi: 10.3389/fneur.2019.00582. eCollection 2019.

5.

Microphysiological Engineering of Self-Assembled and Perfusable Microvascular Beds for the Production of Vascularized Three-Dimensional Human Microtissues.

Paek J, Park SE, Lu Q, Park KT, Cho M, Oh JM, Kwon KW, Yi YS, Song JW, Edelstein HI, Ishibashi J, Yang W, Myerson JW, Kiseleva RY, Aprelev P, Hood ED, Stambolian D, Seale P, Muzykantov VR, Huh D.

ACS Nano. 2019 Jul 23;13(7):7627-7643. doi: 10.1021/acsnano.9b00686. Epub 2019 Jun 18.

PMID:
31194909
6.

Stiffness can mediate balance between hydrodynamic forces and avidity to impact the targeting of flexible polymeric nanoparticles in flow.

Farokhirad S, Ranganathan A, Myerson J, Muzykantov VR, Ayyaswamy PS, Eckmann DM, Radhakrishnan R.

Nanoscale. 2019 Apr 4;11(14):6916-6928. doi: 10.1039/c8nr09594a.

PMID:
30912772
7.

Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain.

Marcos-Contreras OA, Brenner JS, Kiseleva RY, Zuluaga-Ramirez V, Greineder CF, Villa CH, Hood ED, Myerson JW, Muro S, Persidsky Y, Muzykantov VR.

J Control Release. 2019 May 10;301:54-61. doi: 10.1016/j.jconrel.2019.03.008. Epub 2019 Mar 11.

PMID:
30871995
8.

Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems.

Glassman PM, Muzykantov VR.

J Pharmacol Exp Ther. 2019 Sep;370(3):570-580. doi: 10.1124/jpet.119.257113. Epub 2019 Mar 5.

PMID:
30837281
9.

PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake.

Parhiz H, Shuvaev VV, Pardi N, Khoshnejad M, Kiseleva RY, Brenner JS, Uhler T, Tuyishime S, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D, Muzykantov VR.

J Control Release. 2018 Dec 10;291:106-115. doi: 10.1016/j.jconrel.2018.10.015. Epub 2018 Oct 15.

10.

Spatially controlled assembly of affinity ligand and enzyme cargo enables targeting ferritin nanocarriers to caveolae.

Shuvaev VV, Khoshnejad M, Pulsipher KW, Kiseleva RY, Arguiri E, Cheung-Lau JC, LeFort KM, Christofidou-Solomidou M, Stan RV, Dmochowski IJ, Muzykantov VR.

Biomaterials. 2018 Dec;185:348-359. doi: 10.1016/j.biomaterials.2018.09.015. Epub 2018 Sep 12.

11.

Vascular Targeting of Radiolabeled Liposomes with Bio-Orthogonally Conjugated Ligands: Single Chain Fragments Provide Higher Specificity than Antibodies.

Hood ED, Greineder CF, Shuvaeva T, Walsh L, Villa CH, Muzykantov VR.

Bioconjug Chem. 2018 Nov 21;29(11):3626-3637. doi: 10.1021/acs.bioconjchem.8b00564. Epub 2018 Oct 16.

12.

Unintended effects of drug carriers: Big issues of small particles.

Parhiz H, Khoshnejad M, Myerson JW, Hood E, Patel PN, Brenner JS, Muzykantov VR.

Adv Drug Deliv Rev. 2018 May;130:90-112. doi: 10.1016/j.addr.2018.06.023. Epub 2018 Jul 3. Review.

13.

Vascular Immunotargeting: Take the Highway to the First Exit.

Muzykantov VR, Brenner JS.

Hepatology. 2018 Nov;68(5):1672-1674. doi: 10.1002/hep.30141. Epub 2018 Oct 13. No abstract available.

14.

Flexible Nanoparticles Reach Sterically Obscured Endothelial Targets Inaccessible to Rigid Nanoparticles.

Myerson JW, Braender B, Mcpherson O, Glassman PM, Kiseleva RY, Shuvaev VV, Marcos-Contreras O, Grady ME, Lee HS, Greineder CF, Stan RV, Composto RJ, Eckmann DM, Muzykantov VR.

Adv Mater. 2018 Aug;30(32):e1802373. doi: 10.1002/adma.201802373. Epub 2018 Jun 28.

15.

Ferritin-based drug delivery systems: Hybrid nanocarriers for vascular immunotargeting.

Khoshnejad M, Parhiz H, Shuvaev VV, Dmochowski IJ, Muzykantov VR.

J Control Release. 2018 Jul 28;282:13-24. doi: 10.1016/j.jconrel.2018.02.042. Epub 2018 Mar 6. Review.

16.

Ferritin Nanocages with Biologically Orthogonal Conjugation for Vascular Targeting and Imaging.

Khoshnejad M, Greineder CF, Pulsipher KW, Villa CH, Altun B, Pan DC, Tsourkas A, Dmochowski IJ, Muzykantov VR.

Bioconjug Chem. 2018 Apr 18;29(4):1209-1218. doi: 10.1021/acs.bioconjchem.8b00004. Epub 2018 Feb 19.

17.

Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9.

Khoshnejad M, Brenner JS, Motley W, Parhiz H, Greineder CF, Villa CH, Marcos-Contreras OA, Tsourkas A, Muzykantov VR.

Sci Rep. 2018 Jan 29;8(1):1760. doi: 10.1038/s41598-018-19784-2.

18.

Vascular endothelial effects of collaborative binding to platelet/endothelial cell adhesion molecule-1 (PECAM-1).

Kiseleva RY, Greineder CF, Villa CH, Marcos-Contreras OA, Hood ED, Shuvaev VV, DeLisser HM, Muzykantov VR.

Sci Rep. 2018 Jan 24;8(1):1510. doi: 10.1038/s41598-018-20027-7.

19.

Biocompatible coupling of therapeutic fusion proteins to human erythrocytes.

Villa CH, Pan DC, Johnston IH, Greineder CF, Walsh LR, Hood ED, Cines DB, Poncz M, Siegel DL, Muzykantov VR.

Blood Adv. 2018 Feb 13;2(3):165-176. doi: 10.1182/bloodadvances.2017011734.

20.

Biomimetic microfluidic platform for the quantification of transient endothelial monolayer permeability and therapeutic transport under mimicked cancerous conditions.

Uhl CG, Muzykantov VR, Liu Y.

Biomicrofluidics. 2018 Jan 2;12(1):014101. doi: 10.1063/1.5000377. eCollection 2018 Jan.

21.

ICAM-1-targeted thrombomodulin mitigates tissue factor-driven inflammatory thrombosis in a human endothelialized microfluidic model.

Greineder CF, Johnston IH, Villa CH, Gollomp K, Esmon CT, Cines DB, Poncz M, Muzykantov VR.

Blood Adv. 2017 Aug 8;1(18):1452-1465. doi: 10.1182/bloodadvances.2017007229. eCollection 2017 Aug 8.

22.

Targeting superoxide dismutase to endothelial caveolae profoundly alleviates inflammation caused by endotoxin.

Shuvaev VV, Kiseleva RY, Arguiri E, Villa CH, Muro S, Christofidou-Solomidou M, Stan RV, Muzykantov VR.

J Control Release. 2018 Feb 28;272:1-8. doi: 10.1016/j.jconrel.2017.12.025. Epub 2017 Dec 29.

23.

Targeting therapeutics to endothelium: are we there yet?

Kiseleva RY, Glassman PM, Greineder CF, Hood ED, Shuvaev VV, Muzykantov VR.

Drug Deliv Transl Res. 2018 Aug;8(4):883-902. doi: 10.1007/s13346-017-0464-6. Review.

24.

The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series).

Brenner JS, Kiseleva RY, Glassman PM, Parhiz H, Greineder CF, Hood ED, Shuvaev VV, Muzykantov VR.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217752329. doi: 10.1177/2045893217752329. Epub 2017 Dec 20.

25.

Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting.

Greineder CF, Villa CH, Walsh LR, Kiseleva RY, Hood ED, Khoshnejad M, Warden-Rothman R, Tsourkas A, Muzykantov VR.

Bioconjug Chem. 2018 Jan 17;29(1):56-66. doi: 10.1021/acs.bioconjchem.7b00592. Epub 2017 Dec 29.

26.

Up-regulation of NADPH oxidase-mediated redox signaling contributes to the loss of barrier function in KRIT1 deficient endothelium.

Goitre L, DiStefano PV, Moglia A, Nobiletti N, Baldini E, Trabalzini L, Keubel J, Trapani E, Shuvaev VV, Muzykantov VR, Sarelius IH, Retta SF, Glading AJ.

Sci Rep. 2017 Aug 15;7(1):8296. doi: 10.1038/s41598-017-08373-4.

27.

Superoxide Dismutase-Loaded Porous Polymersomes as Highly Efficient Antioxidants for Treating Neuropathic Pain.

Kartha S, Yan L, Weisshaar CL, Ita ME, Shuvaev VV, Muzykantov VR, Tsourkas A, Winkelstein BA, Cheng Z.

Adv Healthc Mater. 2017 Sep;6(17). doi: 10.1002/adhm.201700500. Epub 2017 Jul 3.

28.

Acute administration of catalase targeted to ICAM-1 attenuates neuropathology in experimental traumatic brain injury.

Lutton EM, Razmpour R, Andrews AM, Cannella LA, Son YJ, Shuvaev VV, Muzykantov VR, Ramirez SH.

Sci Rep. 2017 Jun 19;7(1):3846. doi: 10.1038/s41598-017-03309-4.

29.

Mechanism of Collaborative Enhancement of Binding of Paired Antibodies to Distinct Epitopes of Platelet Endothelial Cell Adhesion Molecule-1.

Kiseleva R, Greineder CF, Villa CH, Hood ED, Shuvaev VV, Sun J, Chacko AM, Abraham V, DeLisser HM, Muzykantov VR.

PLoS One. 2017 Jan 13;12(1):e0169537. doi: 10.1371/journal.pone.0169537. eCollection 2017.

30.

Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions.

Brenner JS, Bhamidipati K, Glassman PM, Ramakrishnan N, Jiang D, Paris AJ, Myerson JW, Pan DC, Shuvaev VV, Villa CH, Hood ED, Kiseleva R, Greineder CF, Radhakrishnan R, Muzykantov VR.

Nanomedicine. 2017 May;13(4):1495-1506. doi: 10.1016/j.nano.2016.12.019. Epub 2017 Jan 5.

31.

Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury.

Carnemolla R, Villa CH, Greineder CF, Zaitsev S, Patel KR, Kowalska MA, Atochin DN, Cines DB, Siegel DL, Esmon CT, Muzykantov VR.

FASEB J. 2017 Feb;31(2):761-770. doi: 10.1096/fj.201600912R. Epub 2016 Nov 11.

32.

Biophysically inspired model for functionalized nanocarrier adhesion to cell surface: roles of protein expression and mechanical factors.

Ramakrishnan N, Tourdot RW, Eckmann DM, Ayyaswamy PS, Muzykantov VR, Radhakrishnan R.

R Soc Open Sci. 2016 Jun 29;3(6):160260. doi: 10.1098/rsos.160260. eCollection 2016 Jun.

33.

Size and targeting to PECAM vs ICAM control endothelial delivery, internalization and protective effect of multimolecular SOD conjugates.

Shuvaev VV, Muro S, Arguiri E, Khoshnejad M, Tliba S, Christofidou-Solomidou M, Muzykantov VR.

J Control Release. 2016 Jul 28;234:115-23. doi: 10.1016/j.jconrel.2016.05.040. Epub 2016 May 20.

34.

Targeting vascular (endothelial) dysfunction.

Daiber A, Steven S, Weber A, Shuvaev VV, Muzykantov VR, Laher I, Li H, Lamas S, Münzel T.

Br J Pharmacol. 2017 Jun;174(12):1591-1619. doi: 10.1111/bph.13517. Epub 2016 Jul 4. Review.

35.

Biomimetic channel modeling local vascular dynamics of pro-inflammatory endothelial changes.

Thomas A, Daniel Ou-Yang H, Lowe-Krentz L, Muzykantov VR, Liu Y.

Biomicrofluidics. 2016 Jan 6;10(1):014101. doi: 10.1063/1.4936672. eCollection 2016 Jan.

36.

Molecular engineering of high affinity single-chain antibody fragment for endothelial targeting of proteins and nanocarriers in rodents and humans.

Greineder CF, Hood ED, Yao A, Khoshnejad M, Brenner JS, Johnston IH, Poncz M, Gottstein C, Muzykantov VR.

J Control Release. 2016 Mar 28;226:229-37. doi: 10.1016/j.jconrel.2016.02.006. Epub 2016 Feb 6.

37.

Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles.

Khoshnejad M, Shuvaev VV, Pulsipher KW, Dai C, Hood ED, Arguiri E, Christofidou-Solomidou M, Dmochowski IJ, Greineder CF, Muzykantov VR.

Bioconjug Chem. 2016 Mar 16;27(3):628-37. doi: 10.1021/acs.bioconjchem.5b00641. Epub 2016 Jan 15.

38.

A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation.

Fuentes RE, Zaitsev S, Ahn HS, Hayes V, Kowalska MA, Lambert MP, Wang Y, Siegel DL, Bougie DW, Aster RH, Myers DD, Stepanova V, Cines DB, Muzykantov VR, Poncz M.

J Clin Invest. 2016 Feb;126(2):483-94.

39.

The Role of Carrier Geometry in Overcoming Biological Barriers to Drug Delivery.

Jordan C, Shuvaev VV, Bailey M, Muzykantov VR, Dziubla TD.

Curr Pharm Des. 2016;22(9):1259-73. Review.

PMID:
26675218
40.

Non-affinity factors modulating vascular targeting of nano- and microcarriers.

Myerson JW, Anselmo AC, Liu Y, Mitragotri S, Eckmann DM, Muzykantov VR.

Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):97-112. doi: 10.1016/j.addr.2015.10.011. Epub 2015 Oct 24. Review.

41.

Long-circulating Janus nanoparticles made by electrohydrodynamic co-jetting for systemic drug delivery applications.

Rahmani S, Villa CH, Dishman AF, Grabowski ME, Pan DC, Durmaz H, Misra AC, Colón-Meléndez L, Solomon MJ, Muzykantov VR, Lahann J.

J Drug Target. 2015;23(7-8):750-8. doi: 10.3109/1061186X.2015.1076428.

42.

Targeted endothelial nanomedicine for common acute pathological conditions.

Shuvaev VV, Brenner JS, Muzykantov VR.

J Control Release. 2015 Dec 10;219:576-595. doi: 10.1016/j.jconrel.2015.09.055. Epub 2015 Oct 3. Review.

43.

Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Villa CH, Pan DC, Zaitsev S, Cines DB, Siegel DL, Muzykantov VR.

Ther Deliv. 2015 Jul;6(7):795-826. doi: 10.4155/tde.15.34. Review.

44.

Collaborative Enhancement of Endothelial Targeting of Nanocarriers by Modulating Platelet-Endothelial Cell Adhesion Molecule-1/CD31 Epitope Engagement.

Chacko AM, Han J, Greineder CF, Zern BJ, Mikitsh JL, Nayak M, Menon D, Johnston IH, Poncz M, Eckmann DM, Davies PF, Muzykantov VR.

ACS Nano. 2015 Jul 28;9(7):6785-93. doi: 10.1021/nn505672x. Epub 2015 Jul 13.

45.

Flow shear stress differentially regulates endothelial uptake of nanocarriers targeted to distinct epitopes of PECAM-1.

Han J, Shuvaev VV, Davies PF, Eckmann DM, Muro S, Muzykantov VR.

J Control Release. 2015 Jul 28;210:39-47. doi: 10.1016/j.jconrel.2015.05.006. Epub 2015 May 9.

46.

Dual targeting of therapeutics to endothelial cells: collaborative enhancement of delivery and effect.

Greineder CF, Brenza JB, Carnemolla R, Zaitsev S, Hood ED, Pan DC, Ding BS, Esmon CT, Chacko AM, Muzykantov VR.

FASEB J. 2015 Aug;29(8):3483-92. doi: 10.1096/fj.15-271213. Epub 2015 May 7.

47.

Systems approaches to design of targeted therapeutic delivery.

Myerson JW, Brenner JS, Greineder CF, Muzykantov VR.

Wiley Interdiscip Rev Syst Biol Med. 2015 Sep-Oct;7(5):253-65. doi: 10.1002/wsbm.1304. Epub 2015 May 6. Review.

48.

Nanogel Carrier Design for Targeted Drug Delivery.

Eckmann DM, Composto RJ, Tsourkas A, Muzykantov VR.

J Mater Chem B. 2014 Dec 14;2(46):8085-8097.

49.

Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer.

Li C, Wang J, Hu J, Feng Y, Hasegawa K, Peng X, Duan X, Zhao A, Mikitsh JL, Muzykantov VR, Chacko AM, Pryma DA, Dunn SM, Coukos G.

Oncotarget. 2014 Aug 30;5(16):6994-7012.

50.

Icam-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation.

Ferrer MC, Shuvaev VV, Zern BJ, Composto RJ, Muzykantov VR, Eckmann DM.

PLoS One. 2014 Jul 14;9(7):e102329. doi: 10.1371/journal.pone.0102329. eCollection 2014.

Supplemental Content

Loading ...
Support Center